• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    586.30 +34.59 (+6.27%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Argenx Se ADR

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
    From argenx SE
    Via GlobeNewswire
    The Latest Analyst Ratings For argenx
    Via Benzinga
    argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
    From argenx SE
    Via GlobeNewswire
    Peeling Back The Layers: Exploring argenx Through Analyst Insights
    Via Benzinga
    What 25 Analyst Ratings Have To Say About argenx
    Via Benzinga
    The Analyst Verdict: argenx In The Eyes Of 27 Experts
    Via Benzinga
    Biotech Stocks : Are You A Trader Or A Longer Term Investor?
    Biotech bull market is intact as indicated by large cap biopharma and the best performing funds. 
    Via Talk Markets
    Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
    Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
    Via Investor's Business Daily
    Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
    Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows... 
    Via Benzinga
    Exposures Product Safety
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
    Via Benzinga
    Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
    From argenx SE
    Via GlobeNewswire
    argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    From argenx SE
    Via GlobeNewswire
    Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    From Zai Lab Limited
    Via Business Wire
    argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
    From argenx SE
    Via GlobeNewswire
    Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
    The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030. 
    Via Benzinga
    Exposures Product Safety
    Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
    This is the second approval for the biotech company's drug, Vyvgart Hytrulo. 
    Via Investor's Business Daily
    Exposures Product Safety
    Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
    Via Benzinga
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    From argenx SE
    Via GlobeNewswire
    After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
    Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday. 
    Via Investor's Business Daily
    Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
    Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.